MOTS-c
Pending PCACAlso known as: Mitochondrial Open Reading Frame of the 12S rRNA-c
Metabolic & LongevityLast reviewed: April 28, 2026
A mitochondria-derived peptide encoded by the 12S rRNA gene. Naturally produced in the body and declines with age. Emerging research shows remarkable effects on metabolism, insulin sensitivity, and exercise capacity.
Mechanism of Action
Acts as a metabolic regulator that activates AMPK, promotes glucose uptake, reduces fat accumulation, and enhances mitochondrial function. Translates mitochondrial stress signals into adaptive cellular responses. Shown to extend lifespan in mouse models.
Common Uses
- Metabolic health optimization
- Insulin sensitivity improvement
- Obesity treatment (investigational)
- Osteoporosis prevention
- Exercise performance enhancement
Known Risks
- Very limited human clinical data
- Optimal dosing not established
- Long-term effects unknown
- Injection site reactions
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 for obesity and osteoporosis indications. One of the more scientifically novel compounds on the PCAC list, with strong preclinical data but limited human trials. Compounding not yet authorized.
Get notified when the PCAC decides on MOTS-c
Scheduled review: July 23, 2026. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
5–10 mg
Frequency
2–3x per week
Cycle Length
4–8 weeks
Emerging compound — dosing protocols are not well-established. Often used alongside exercise for metabolic optimization. Stack with Humanin for combined mitochondrial support.
Related Compounds
Research References
Related Articles
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.